- Home
- URGN vs AVO Comparison
URGN vs AVO Comparison
Compare URGN & AVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- AVO
- Stock Information
- Founded
- URGN 2004
- AVO 1983
- Country
- URGN United States
- AVO United States
- Employees
- URGN N/A
- AVO N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- AVO Farming/Seeds/Milling
- Sector
- URGN Health Care
- AVO Consumer Staples
- Exchange
- URGN Nasdaq
- AVO Nasdaq
- Market Cap
- URGN 673.5M
- AVO 734.6M
- IPO Year
- URGN 2017
- AVO 2020
- Fundamental
- Price
- URGN $13.23
- AVO $10.73
- Analyst Decision
- URGN Strong Buy
- AVO Strong Buy
- Analyst Count
- URGN 4
- AVO 4
- Target Price
- URGN $48.38
- AVO $12.38
- AVG Volume (30 Days)
- URGN 527.9K
- AVO 114.8K
- Earning Date
- URGN 08-13-2024
- AVO 09-09-2024
- Dividend Yield
- URGN N/A
- AVO N/A
- EPS Growth
- URGN N/A
- AVO N/A
- EPS
- URGN N/A
- AVO 0.25
- Revenue
- URGN $85,011,000.00
- AVO $1,075,600,000.00
- Revenue This Year
- URGN $16.20
- AVO $8.19
- Revenue Next Year
- URGN $56.87
- AVO N/A
- P/E Ratio
- URGN N/A
- AVO $43.16
- Revenue Growth
- URGN 17.22
- AVO 9.11
- 52 Week Low
- URGN $10.60
- AVO $8.19
- 52 Week High
- URGN $20.70
- AVO $13.00
- Technical
- Relative Strength Index (RSI)
- URGN 33.98
- AVO 56.07
- Support Level
- URGN $13.40
- AVO $10.61
- Resistance Level
- URGN $14.38
- AVO $10.97
- Average True Range (ATR)
- URGN 0.68
- AVO 0.22
- MACD
- URGN -0.07
- AVO 0.04
- Stochastic Oscillator
- URGN 3.27
- AVO 66.20
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About AVO Mission Produce Inc.
Mission Produce Inc is engaged in the business of producing and distributing avocados, serving retail, wholesale, and food service customers. Also, the company provides additional services like ripening, bagging, custom packing, and logistical management. The company's operating segments include Marketing and Distribution and International Farming and Blueberries. It generates maximum revenue from the Marketing and Distribution segment. The Marketing and Distribution segment sources fruit mainly from growers and then distributes fruit through a distribution network.